The stock of Pfizer Inc. (NYSE:PFE) is a huge mover today! About 51.23M shares traded hands or 92.67% up from the average. Pfizer Inc. (NYSE:PFE) has declined 1.17% since April 8, 2016 and is downtrending. It has underperformed by 6.82% the S&P500.
The move comes after 9 months positive chart setup for the $217.46 billion company. It was reported on Nov, 10 by Barchart.com. We have $53.92 PT which if reached, will make NYSE:PFE worth $132.65 billion more.
Pfizer Inc. (NYSE:PFE) Ratings Coverage
Out of 18 analysts covering Pfizer (NYSE:PFE), 7 rate it a “Buy”, 0 “Sell”, while 11 “Hold”. This means 39% are positive. Pfizer has been the topic of 38 analyst reports since July 29, 2015 according to StockzIntelligence Inc. The stock has “Buy” rating given by Jefferies on Monday, June 20. The firm has “Hold” rating given on Wednesday, April 6 by Societe Generale. On Wednesday, November 2 the stock rating was downgraded by BMO Capital Markets to “Market Perform”. Piper Jaffray maintained it with “Overweight” rating and $51 target price in Saturday, September 5 report. The rating was maintained by Argus Research on Tuesday, November 3 with “Buy”. Jefferies maintained Pfizer Inc. (NYSE:PFE) on Thursday, August 4 with “Buy” rating. The firm has “Buy” rating given on Wednesday, July 29 by Argus Research. The firm earned “Neutral” rating on Wednesday, November 25 by SunTrust. The rating was downgraded by Argus Research on Wednesday, November 2 to “Hold”. The stock of Pfizer Inc. (NYSE:PFE) has “Buy” rating given on Tuesday, June 14 by Jefferies.
According to Zacks Investment Research, “Pfizer Inc. is a research-based, global pharmaceutical company that discovers, develops, manufactures, and markets medicines for humans and animals. The Company’s diversified global healthcare portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and consumer healthcare products. Pfizer’s Animal Health business unit discovers, develops and sells products for the prevention and treatment of diseases in livestock and companion animals. It sells its products to wholesalers, distributors, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, veterinarians, livestock producers, and grocery and convenience stores. Pfizer Inc. is headquartered in New York.”
Insitutional Activity: The institutional sentiment decreased to 1.03 in Q2 2016. Its down 0.21, from 1.24 in 2016Q1. The ratio dropped, as 80 funds sold all Pfizer Inc. shares owned while 704 reduced positions. 127 funds bought stakes while 678 increased positions. They now own 4.15 billion shares or 5.76% less from 4.40 billion shares in 2016Q1.
Madison holds 0.72% of its portfolio in Pfizer Inc. (NYSE:PFE) for 989,841 shares. Valley Natl Advisers Inc has 0.59% invested in the company for 32,502 shares. Wafra Inv Advisory Grp Ny has invested 3.31% of its portfolio in Pfizer Inc. (NYSE:PFE). Shoker Inv Counsel accumulated 1.1% or 35,183 shares. Independence has 14,187 shares for 0.77% of their US portfolio. Clean Yield Grp accumulated 0.78% or 51,548 shares. The Kentucky-based Argi Inv Service Limited Liability has invested 0.06% in Pfizer Inc. (NYSE:PFE). Prudential Fin Incorporated, a New Jersey-based fund reported 13.54M shares. Dai Ichi Life Ins Limited holds 0.9% or 845,312 shares in its portfolio. Davidson And Garrard last reported 163,026 shares in the company. Meritage Port Management has 152,008 shares for 0.6% of their US portfolio. Lifeplan Grp Inc Incorporated holds 0.31% or 12,814 shares in its portfolio. Cambridge Tru Com has 0.93% invested in the company for 345,200 shares. The New York-based Pura Vida Invs Llc has invested 1.76% in Pfizer Inc. (NYSE:PFE). Teacher Retirement Sys Of Texas owns 5.99 million shares or 1.44% of their US portfolio.
Insider Transactions: Since May 11, 2016, the stock had 0 insider purchases, and 3 insider sales for $6.92 million net activity. $3.45M worth of Pfizer Inc. (NYSE:PFE) shares were sold by DAMELIO FRANK A. BOURLA ALBERT had sold 18,390 shares worth $552,530. $2.92M worth of Pfizer Inc. (NYSE:PFE) was sold by CANGIALOSI LORETTA V on Tuesday, May 24. 4,700 shares with value of $157,450 were sold by OLSON LAURIE J on Wednesday, May 11.
More notable recent Pfizer Inc. (NYSE:PFE) news were published by: Foxbusiness.com which released: “Better Buy: Gilead Sciences Inc. vs. Pfizer Inc.” on November 09, 2016, also Profitconfidential.com with their article: “Pfizer Inc. (NYSE:PFE): Why Is PFE Stock Going Nuts Today?” published on November 09, 2016, Bloomberg.com published: “Pfizer Ends Cholesterol Drug Trials as Earnings Fall Short” on November 01, 2016. More interesting news about Pfizer Inc. (NYSE:PFE) were released by: Reuters.com and their article: “Exclusive: Pfizer weighs sale or spin-off of consumer health unit – source…” published on November 09, 2016 as well as Forbes.com‘s news article titled: “Ex-Dividend Reminder: Pfizer, ResMed and EverBank Financial” with publication date: November 04, 2016.
PFE Company Profile
Pfizer Inc. (Pfizer), incorporated on June 2, 1942, is a research global biopharmaceutical company. The Firm is engaged in discovering, developing and manufacturing of healthcare products. The Company’s divisions include Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The Company’s portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. The Company’s biopharmaceutical products include Lipitor, Sutent and the Premarin family of products. The Company’s biotechnology products include BeneFIX, ReFacto and Xyntha.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.